Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IVB Prostate Cancer AJCC v8: early-phase trial registry
27 of 46 indexed Stage IVB Prostate Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #312 of 28,707 conditions by registered trial count.
46 US clinical trials · 27 currently recruiting · #312 of 28,707 conditions by registered trial count
Stage IVB Prostate Cancer AJCC v8: 46 US clinical trials tracked, 27 recruiting.
Stage IVB Prostate Cancer AJCC v8 is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition stage-ivb-prostate-cancer-ajcc-v8
OPEN 27 | RECR 59% | LATE 5 | EARLY 39 | RANK #312 | SPON 6
Volume-matched condition peers
Nearest open-share peer: HPV Positive Oropharyngeal Squamous Cell Carcinoma (59% recruiting · 17 trials)
Stage IVB Prostate Cancer AJCC v8 lists 27 open slots (59% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IVB Prostate Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IVB Prostate Cancer AJCC v8 is recruiting above its size-band peers.
27 of 46 indexed trials (58.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Stage IVB Prostate Cancer AJCC v8 trials is spread across many organizations.
Jonsson Comprehensive Cancer Center accounts for 6 of 46 trials (13%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IVB Prostate Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 61 among the 46 trials that report a genuine target (sentinel values excluded). 31 of those (67.4%) plan for fewer than 100 participants.
-
Stage IVB Prostate Cancer AJCC v8 research is mostly interventional.
45 interventional and 1 observational studies make up this index (97.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
46 total, page 1 of 1
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
NCT03678025
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
NCT06931340
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group
NCT04423211
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
NCT06470243
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Alliance for Clinical Trials in Oncology
NCT06632977
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
NCT06200103
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
M.D. Anderson Cancer Center
NCT05054296
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
NCT05053152
Addressing Health Literacy With a Tailored Survivorship Care Plan
Emory University
NCT06674863
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
NCT06244004
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Jonsson Comprehensive Cancer Center
NCT04915508
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
NCT04071236
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
NCT04734730
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
NCT06039371
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
NCT06526299
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
NCT04489719
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT06236139
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
NCT06288113
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
NCT06616155
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
University of Utah
NCT05168618
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
NCT05398302
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
NCT05113537
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
NCT07219147
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
NCT05805371
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT06145633
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
NCT06305598
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
NCT03317392
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
NCT04777071
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
Jonsson Comprehensive Cancer Center
NCT05496959
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
Alliance for Clinical Trials in Oncology
NCT05241860
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT04388852
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology
NCT04455750
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal
NCT04471974
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT03821792
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT03902951
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
National Cancer Institute (NCI)
NCT05828082
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Thomas Hope
NCT04716725
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
NCT03873805
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
NCT05689021
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
NCT04267887
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
NCT05924672
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04050215
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03204812
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
NCT05730712
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 26 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IVB Prostate Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IVB Prostate Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IVB Prostate Cancer AJCC v8 page
46 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Stage IVB Prostate Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonsson Comprehensive Cancer Center sponsors the most Stage IVB Prostate Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IVB Prostate Cancer AJCC v8 condition card totals 46 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.